Viatris (VTRS) Cash from Investing Activities (2019 - 2026)
Viatris (VTRS) recorded quarterly Cash from Investing Activities of $277.4 million in Q1 2026, up 231.34% quarter-over-quarter from -$211.2 million in Q4 2025, and up 526.11% on a YoY basis from $44.3 million in Q1 2025.
Viatris (VTRS) Cash from Investing Activities (2019 - 2026) Analysis & Trends
Viatris' Cash from Investing Activities history runs 8 years deep, the most recent figure standing at $277.4 million for Q1 2026.
- In Q1 2026, Cash from Investing Activities rose 526.11% year-over-year to $277.4 million; the TTM figure through Mar 2026 stood at -$85.2 million (down 104.51% YoY), while the FY2025 annual figure was -$427.7 million, down 123.75% from the prior year.
- Cash from Investing Activities was $277.4 million for Q1 2026 at Viatris, up from -$211.2 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $1.7 billion in Q3 2024 to a low of -$749.5 million in Q1 2023.
- Historically, Cash from Investing Activities has averaged $132.9 million across 5 years, with a median of -$66.9 million in 2022.
- The sharpest annual moves came in 2023 and 2024: Cash from Investing Activities sank 1020.33% in 2023, then soared 3283.79% in 2024.
- A 5-year view of Cash from Investing Activities shows it stood at $1.7 billion in 2022, then sank by 98.46% to $26.7 million in 2023, then tumbled by 731.84% to -$168.7 million in 2024, then fell by 25.19% to -$211.2 million in 2025, then surged by 231.34% to $277.4 million in 2026.
- The last three Cash from Investing Activities figures came in at $277.4 million (Q1 2026), -$211.2 million (Q4 2025), and -$98.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 229.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | -87.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 743.70 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | -506.20 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | -60.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -2.08 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -15.45 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 25.99 Mn |
| 10 | Viatris | - | - | 1.16 Bn | 277.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 277.40 Mn |
| Mar 31, 2026 | 277.40 Mn |
| Dec 31, 2025 | -211.20 Mn |
| Dec 31, 2025 | -211.20 Mn |
| Sep 30, 2025 | -98.90 Mn |
| Sep 30, 2025 | -98.90 Mn |
| Jun 30, 2025 | -52.50 Mn |
| Jun 30, 2025 | -52.50 Mn |
| Mar 31, 2025 | -65.10 Mn |
| Mar 31, 2025 | -65.10 Mn |
| Dec 31, 2024 | -168.70 Mn |
| Dec 31, 2024 | -168.70 Mn |
| Sep 30, 2024 | 1.75 Bn |
| Sep 30, 2024 | 1.75 Bn |
| Jun 30, 2024 | 375.80 Mn |
| Jun 30, 2024 | 375.80 Mn |
| Mar 31, 2024 | -154.30 Mn |
| Mar 31, 2024 | -154.30 Mn |
| Dec 31, 2023 | 26.70 Mn |
| Dec 31, 2023 | 26.70 Mn |